University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

o-Nitroanisole (CAS 91-23-6)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
hmo kid lgi ubl hmo kid lgi ubl liv liv 15.6m,v 178m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   hmo = hematopoietic system. kid = kidney. lgi = large intestine. liv = liver. ubl = urinary bladder. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

o-Nitroanisole: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

o-NITROANISOLE 91-23-6 4313 M f b6c eat 24m24 TR416 : 0 85.7mg 255.mg 767.mg --- MXA 153.mg Z P<.008 67.1mg 3.07gm 5/50 14/50 (14/50 5/50) ---:mlh,mlm,mlp,mlu. S liv hpa 179.mg Z P<.0005 p 96.6mg 695.mg 14/50 20/50 36/50 (18/50) liv MXA 194.mg Z P<.003 p 99.4mg 1.09gm 17/50 21/50 37/50 (20/50) liv:hpa,hpc. TBA MXB 350.mg Z P<.3 104.mg n.s.s. 39/50 44/50 47/50 (28/50) liv MXB 194.mg Z P<.003 99.1mg 1.13gm 17/50 22/50 37/50 (20/50) liv:hpa,hpb,hpc. lun MXB no dre P=1. 1.02gm n.s.s. 6/50 3/50 3/50 (0/50) lun:a/a,a/c. 4314 M m b6c eat 24m24 TR416 : 0 79.2mg 237.mg 710.mg liv hpa 177.mg Z P<.002 c 95.4mg 724.mg 14/50 26/50 41/50 (29/50) liv MXB 198.mg Z P<.006 97.0mg 2.44gm 21/50 33/50 46/50 (34/50) liv:hpa,hpb,hpc. C liv MXA 208.mg Z P<.007 c 101.mg 3.82gm 21/50 32/50 45/50 (32/50) liv:hpa,hpc. liv MXA 391.mg Z P<.005 c 194.mg 4.17gm 7/50 14/50 23/50 (15/50) liv:hpb,hpc. liv hpb 428.mg Z P<.0005 c 251.mg 825.mg 0/50 3/50 17/50 (9/50) liv hpc no dre P=1. 1.99gm n.s.s. 7/50 12/50 11/50 7/50 TBA MXB 43.5gm * P<1. 531.mg n.s.s. 38/50 41/50 49/50 41/50 liv MXB 198.mg Z P<.006 97.0mg 2.44gm 21/50 33/50 46/50 (34/50) liv:hpa,hpb,hpc. lun MXB no dre P=1. 3.36gm n.s.s. 6/50 12/50 4/50 4/50 lun:a/a,a/c. 4315 R f f34 eat 24m24 TR416 : 0 11.0mg 32.9mg 98.9mg --- mnl 152.mg * P<.006 p 71.8mg 1.85gm 14/50 11/50 14/50 26/50 lun a/a 666.mg * P<.02 251.mg n.s.s. 0/50 0/50 2/50 3/50 S liv hpa 1.01gm * P<.02 307.mg n.s.s. 0/50 0/50 0/50 3/50 S for MXA 1.27gm * P<.2 e 313.mg n.s.s. 0/50 1/50 0/50 2/50 for:sqc,sqp. for sqp 3.27gm * P<.5 e 404.mg n.s.s. 0/50 1/50 0/50 1/50 TBA MXB 336.mg * P<.7 52.3mg n.s.s. 46/50 46/50 46/50 46/50 liv MXB 1.01gm * P<.02 307.mg n.s.s. 0/50 0/50 0/50 3/50 liv:hpa,hpb,hpc. 4316 R f f34 eat 6m24 TR416a : 0 77.9mg 234.mg MXB MXB 12.9mg / P<.0005 6.72mg 23.8mg 0/22 20/20 32/34 kid:tcc,tpp; lgi:adp,car; ubl:sar,sqc,sqp,tcc,tpp. C ubl MXA 13.0mg / P<.0005 c 6.74mg 24.0mg 0/22 19/20 32/34 ubl:tcc,tpp. ubl tcc 13.2mg / P<.0005 c 6.81mg 24.8mg 0/22 18/20 32/34 lgi adp 55.0mg / P<.0005 c 24.6mg 114.mg 0/22 5/20 17/34 lgi MXA 55.0mg / P<.0005 c 24.6mg 114.mg 0/22 5/20 17/34 lgi:adp,car. col adp 60.9mg / P<.0005 26.0mg 130.mg 0/22 4/20 17/34 S ubl sar 192.mg / P<.0005 c 73.8mg 544.mg 0/22 1/20 9/34 ubl MXA 588.mg * P<.003 c 208.mg 3.24gm 0/22 0/20 5/34 ubl:sqc,sqp. ubl sqp 751.mg * P<.006 c 236.mg 9.40gm 0/22 0/20 4/34 ubl tpp 543.mg * P<.07 c 99.4mg n.s.s. 0/22 1/20 1/34 kid MXA 1.24gm * P<.04 c 287.mg n.s.s. 0/22 0/20 2/34 kid:tcc,tpp. col car 1.30gm * P<.04 317.mg n.s.s. 0/22 0/20 2/34 S lgi car 1.30gm * P<.04 c 317.mg n.s.s. 0/22 0/20 2/34 rec adp 560.mg * P<.2 91.3mg n.s.s. 0/22 1/20 0/34 kid tpp 1.89gm * P<.2 c 309.mg n.s.s. 0/22 0/20 1/34 ubl sqc 2.70gm * P<.2 c 439.mg n.s.s. 0/22 0/20 1/34 kid tcc 3.55gm * P<.2 c 578.mg n.s.s. 0/22 0/20 1/34 TBA MXB 10.7mg / P<.0005 5.84mg 22.2mg 19/22 20/20 32/34 liv MXB no dre P=1. n.s.s. n.s.s. 0/22 0/20 0/34 liv:hpa,hpb,hpc. 4317 R m f34 eat 24m24 TR416 : 0 8.75mg 26.2mg 79.0mg tes MXA 21.3mg * P<.0005 11.8mg 63.4mg 48/50 45/50 45/50 45/51 tes:iab,ica. S --- mnl 25.9mg * P<.0005 p 15.1mg 62.1mg 26/50 25/50 42/50 34/51 amd MXA 89.6mg * P<.004 39.4mg 767.mg 7/50 7/50 8/50 10/51 amd:pbb,pob. S kid MXA 251.mg * P<.005 e 93.2mg 3.11gm 0/50 1/50 1/50 3/51 kid:rua,ruc. for MXA 304.mg * P<.007 e 102.mg 5.23gm 0/50 0/50 2/50 2/51 for:sqc,sqp. amd MXA 109.mg * P<.04 40.9mg n.s.s. 12/50 10/50 10/50 10/51 amd:pbb,phm,pob. S pre MXA 195.mg * P<.04 68.6mg n.s.s. 7/50 4/50 3/50 8/51 pre:car,cnb. S for sqp 543.mg * P<.05 e 134.mg n.s.s. 0/50 0/50 1/50 1/51 kid ruc 612.mg * P<.02 e 149.mg n.s.s. 0/50 0/50 0/50 2/51 for sqc 715.mg * P<.07 e 167.mg n.s.s. 0/50 0/50 1/50 1/51 kid rua 435.mg * P<.2 e 127.mg n.s.s. 0/50 1/50 1/50 1/51 TBA MXB 21.4mg * P<.0005 12.1mg 59.4mg 48/50 44/50 48/50 47/51 liv MXB 330.mg * P<.2 78.5mg n.s.s. 0/50 4/50 1/50 2/51 liv:hpa,hpb,hpc. 4318 R m f34 eat 6m24 TR416a : 0 62.3mg 187.mg MXB MXB 7.47mg / P<.0005 2.84mg 14.0mg 0/21 26/27 34/34 kid:tcc,tpp; lgi:adp,car; ubl:sar,sqc,sqp,tcc,tpp. C ubl MXA 7.48mg / P<.0005 c 2.84mg 14.1mg 0/21 26/27 33/34 ubl:tcc,tpp. ubl tcc 8.28mg / P<.0005 c 2.93mg 16.4mg 0/21 23/27 33/34 lgi MXA 8.54mg / P<.0005 c 2.96mg 17.9mg 0/21 21/27 25/34 lgi:adp,car. lgi adp 8.58mg / P<.0005 c 2.96mg 18.0mg 0/21 21/27 24/34 col adp 17.2mg / P<.0005 7.65mg 29.1mg 0/21 18/27 24/34 S rec adp 51.8mg * P<.0005 15.7mg 212.mg 0/21 6/27 1/34 S ubl tpp 75.6mg * P<.004 c 17.0mg 965.mg 0/21 3/27 1/34 kid MXA 83.6mg * P<.0005 c 16.8mg 468.mg 0/21 1/27 9/34 kid:tcc,tpp. kid tcc 90.9mg * P<.0005 c 17.0mg 806.mg 0/21 1/27 6/34 ubl MXA 273.mg / P<.0005 c 117.mg 801.mg 0/21 0/27 8/34 ubl:sqc,sqp. ubl sar 292.mg * P<.0005 c 117.mg 994.mg 0/21 1/27 7/34 ubl sqc 422.mg / P<.002 c 147.mg 2.04gm 0/21 0/27 5/34 ubl sqp 482.mg / P<.003 c 155.mg 3.27gm 0/21 0/27 4/34 lgi car 573.mg * P<.004 c 194.mg 4.36gm 0/21 0/27 4/34 col car 573.mg * P<.004 194.mg 4.36gm 0/21 0/27 4/34 S cec adp 21.3mg * P<.03 3.48mg n.s.s. 0/21 1/27 0/34 S kid tpp 1.04gm * P<.03 c 291.mg n.s.s. 0/21 0/27 3/34 TBA MXB 3.97mg / P<.0005 1.92mg 8.76mg 19/21 27/27 34/34 liv MXB no dre P=1. 12.8mg n.s.s. 1/21 0/27 0/34 liv:hpa,hpb,hpc.

Mutagenicity in Salmonella: positive
SMILES Code for o-Nitroanisole: COC1=C(C=CC=C1)[N+](=O)[O-]
InChI Code for o-Nitroanisole: InChI=1/C7H7NO3/c1-11-7-5-3-2-4-6(7)8(9)10/h2-5H,1H3
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for o-Nitroanisole: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10